Eton Pharmaceuticals, Inc. (ETON) Stock Price, Quote & News - Stock Analysis

Eton Pharmaceuticals, Inc. (ETON)

NASDAQ: ETON · IEX Real-Time Price · USD
3.580
-0.020 (-0.56%)
At close: May 24, 2024, 4:00 PM
3.640
+0.060 (1.68%)
After-hours: May 24, 2024, 4:07 PM EDT
-0.56%
Market Cap 91.97M
Revenue (ttm) 35.30M
Net Income (ttm) 913,000
Shares Out 25.69M
EPS (ttm) 0.04
PE Ratio 89.50
Forward PE 43.87
Dividend n/a
Ex-Dividend Date n/a
Volume 224,448
Open 3.641
Previous Close 3.600
Day's Range 3.540 - 3.650
52-Week Range 2.420 - 5.810
Beta 1.19
Analysts Strong Buy
Price Target 9.00 (+151.4%)
Earnings Date May 9, 2024

About ETON

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortison... [Read more]

Sector Healthcare
IPO Date Nov 13, 2018
Employees 30
Stock Exchange NASDAQ
Ticker Symbol ETON
Full Company Profile

Financial Performance

In 2023, ETON's revenue was $32.64 million, an increase of 42.60% compared to the previous year's $22.89 million. Losses were -$936,000, -89.62% less than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ETON stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 151.40% from the latest price.

Price Target
$9.0
(151.40% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Eton Pharmaceuticals Reports First Quarter 2024 Financial Results

•  Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth•  Acquired PKU GOLIKE®, launched Nitisinone, and submitted a n...

16 days ago - GlobeNewsWire

Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases,...

24 days ago - GlobeNewsWire

Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak sales of more than $50 million annually -- Produ...

25 days ago - GlobeNewsWire

Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing ...

26 days ago - GlobeNewsWire

Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE

GENEVA, SWITZERLAND / ACCESSWIRE / March 22, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering in...

2 months ago - Accesswire

Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria

DEER PARK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing t...

2 months ago - GlobeNewsWire

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

DEER PARK, Ill., March 14, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing t...

2 months ago - GlobeNewsWire

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024

DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing t...

3 months ago - GlobeNewsWire

Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation

DEER PARK, Ill., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatme...

3 months ago - GlobeNewsWire

Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules

-- Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* ---- Current Nitisinone market is estimated to exceed $50 million annually ---- Product is now availa...

4 months ago - GlobeNewsWire

Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results

DEER PARK, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...

7 months ago - GlobeNewsWire

Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

DEER PARK, Ill., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to add...

7 months ago - GlobeNewsWire

Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone

-- Expect Q1 2024 product launch ---- Nitisinone market estimated to be more than $50 million annually ---- Eton will offer Eton Cares support program to all patients -- DEER PARK, Ill., Oct. 04, 2023...

8 months ago - GlobeNewsWire

Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

DEER PARK, Ill., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases...

9 months ago - GlobeNewsWire

Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results

DEER PARK, Ill., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...

10 months ago - GlobeNewsWire

Eton Pharmaceuticals to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

DEER PARK, Ill., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare disease...

10 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eton Pharmaceuticals, Inc. - ETON

NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ: ETON).   Such investors are advis...

11 months ago - PRNewsWire

Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection

DEER PARK, Ill., June 28, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases...

11 months ago - GlobeNewsWire

Eton Pharmaceuticals Reports First Quarter 2023 Financial Results

DEER PARK, Ill., May 11, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tre...

1 year ago - GlobeNewsWire

Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane® (betaine anhydrous for oral solution)

-- Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* ---- Product is now available exclusively through Optime Care -- DEER PARK, Ill., May 10, 2023 (GLOBE...

1 year ago - GlobeNewsWire

Eton Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

DEER PARK, Ill., May 03, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases...

1 year ago - GlobeNewsWire

Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results

DEER PARK, Ill., March 16, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing t...

1 year ago - GlobeNewsWire

Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600

-- Product is targeting rare pediatric endocrinology condition ---- Potential for NDA submission in Q2 2024 -- DEER PARK, Ill., March 15, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the ...

1 year ago - GlobeNewsWire

Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023

DEER PARK, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseas...

1 year ago - GlobeNewsWire

Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection

-- Product previously granted orphan drug designation for methanol poisoning ---- Application assigned a PDUFA date of June 27, 2023 -- DEER PARK, Ill., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Eton Pharmace...

1 year ago - GlobeNewsWire